Apogee Therapeutics, Inc. financial data

Symbol
APGE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
221 Crescent St., Building 17, Suite 102 B, Waltham, Massachusetts
Fiscal year end
December 31
Former names
Apogee Therapeutics, LLC (to 6/12/2023)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.31 K %
Return On Assets -23.2 %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 56.4 M shares
Entity Public Float 0 USD
Common Stock, Value, Issued 1 K USD
Weighted Average Number of Shares Outstanding, Basic 50.2 M shares +904%
Weighted Average Number of Shares Outstanding, Diluted 50.2 M shares +904%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 88.7 M USD +240%
General and Administrative Expense 29.8 M USD +125%
Operating Income (Loss) -119 M USD -202%
Net Income (Loss) Attributable to Parent -104 M USD -116%
Earnings Per Share, Basic -1.49 USD/shares +74.5%
Earnings Per Share, Diluted -1.49 USD/shares +74.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 485 M USD +243%
Marketable Securities, Current 331 M USD
Other Assets, Current 2.72 M USD
Assets, Current 821 M USD
Property, Plant and Equipment, Net 699 K USD
Operating Lease, Right-of-Use Asset 1.95 M USD
Other Assets, Noncurrent 401 K USD
Assets 824 M USD
Accounts Payable, Current 4.3 M USD
Employee-related Liabilities, Current 2.29 M USD
Accrued Liabilities, Current 16.1 M USD
Liabilities, Current 21.6 M USD
Operating Lease, Liability, Noncurrent 630 K USD
Liabilities 22.2 M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -177 K USD
Retained Earnings (Accumulated Deficit) -156 M USD
Liabilities and Equity 824 M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.6 M USD -200%
Net Cash Provided by (Used in) Financing Activities 451 M USD
Net Cash Provided by (Used in) Investing Activities -51.7 M USD
Common Stock, Shares Authorized 400 M shares
Common Stock, Shares, Issued 58.5 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 367 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 486 M USD +244%
Deferred Tax Assets, Valuation Allowance 30.2 M USD +352%
Deferred Tax Assets, Gross 30.8 M USD +360%
Operating Lease, Liability 2.03 M USD
Depreciation 29 K USD
Payments to Acquire Property, Plant, and Equipment 351 K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -32.6 M USD -160%
Lessee, Operating Lease, Liability, to be Paid 2.21 M USD
Operating Lease, Liability, Current 1.14 M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 964 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.24 M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 174 K USD
Deferred Tax Assets, Operating Loss Carryforwards 5.37 M USD +766%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares
Unrecognized Tax Benefits 904 K USD
Additional Paid in Capital 958 M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 4.19 M USD +229%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares